💬In plain words
What the trial is, and whether it could suit you
This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
Inclusion Criteria:
* Mild to moderate aortic stenosis (peak aortic jet velocity ≥2.5 and \<4m/s)
* Normal left ventricular ejection fraction (i.e. ≥50%)
* Systolic blood pressure \>110 mmHg
* Diastolic blood pressure \>70 mmHg
Exclusion Criteria:
* More than mild aortic or mitral regurgitation, or mitral stenosis
* Current use or documented indication for renin-angiotensin system medication or Aliskiren
* Known allergy or intolerance to angiotensin II receptor blockers (ARBs)
* Alzheimer, dementia or known non-compliant patient
* Renal dysfunction (glomerular filtration rate \<30ml/min/1.73m2)
* Chronic hyperkalemia
* Diagnosed hepatic failure, cirrhosis, hepatitis or history of hepatic impairment
* Newly diagnosed (\<2 months) or poorly controlled diabetes
* Pre-existing obstructive coronary artery disease with CCS III-IV angina or recent myocardial infarction (\<3 months)
* Pregnant or lactating women
* Patients unable to read, understand or sign research consent
💊
What it tests
- Angiotensin Receptor Blockers
- Placebo
CRIUCPQ
Québec, Canada
Odense University Hospital
Odense, Denmark
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.